ACADIA Pharmaceuticals (ACAD) : Investors lapped up stocks on upticks to the tune of $1.74 million in the Fridays trading session. The trading value on downticks was comparatively at $1.52 million and the uptick to downtick ratio of 1.14 indicates continuous buying by the bulls. The net money flow into the stock was $0.21 million. Upticks saw transactions worth $0.57 clearly indicating buying by large investors. The total money flow for block trades stood at $0.57 million, which is a positive for the stock in the long-term. ACADIA Pharmaceuticals (ACAD) fell $0.51 during the day at $31.59, a drop of -1.59% over the previous days close. However, for the week, the stock is -3.86%, compared to the previous week.
The company Insiders own 21.65% of ACADIA Pharmaceuticals shares according to the proxy statements. Institutional Investors own 92.28% of ACADIA Pharmaceuticals shares.
In a related news, Harrigan Edmund, 0 of Acadia Pharmaceuticals Inc had purchased 1,000 shares on August 16, 2016 in a transaction. The price per share was $32.97 and the total amount of the disclosed transaction was $32,970.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
ACADIA Pharmaceuticals (NASDAQ:ACAD): stock was range-bound between the intraday low of $31.02 and the intraday high of $32.4 after having opened at $32.2 on Fridays session. The stock finally closed in the red at $32.2, a loss of -1.59%. The stock remained in the red for the whole trading day. The total traded volume was 1,525,562 shares. The stock failed to cross $32.4 in Fridays trading. The stocks closing price on Thursday was $32.1.
ACADIA Pharmaceuticals (ACAD) : During the past 4 weeks, traders have been relatively bearish on ACADIA Pharmaceuticals (ACAD), hence the stock is down -13.31% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.35% relative to the S&P 500. The 4-week change in the price of the stock is -13.43% and the stock has fallen -3.86% in the past 1 week.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.